Stockscreener 앱 받기
114.30
0.22%
0.25
시장 영업 전:
114.65
0.35
+0.31%
전일 마감가:
$114.05
열려 있는:
$114.19
하루 거래량:
1.31M
Relative Volume:
0.63
시가총액:
$6.61B
수익:
$76.81M
순이익/손실:
$-162.42M
주가수익비율:
-38.23
EPS:
-2.99
순현금흐름:
$-122.49M
1주 성능:
+0.47%
1개월 성능:
+64.74%
6개월 성능:
+58.40%
1년 성능:
+74.16%
1일 변동 폭
$114.07
$114.65
1주일 범위
$113.68
$114.65
52주 변동 폭
$47.86
$114.65
Arcellx Inc Stock (ACLX) Company Profile
명칭
Arcellx Inc
전화
240-327-0603
주소
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
114.30 | 6.59B | 76.81M | -162.42M | -122.49M | -2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 다운그레이드 | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-22 | 개시 | Wells Fargo | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-16 | 개시 | Stifel | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-03-07 | 개시 | Morgan Stanley | Overweight |
| 2024-01-04 | 재확인 | Needham | Buy |
| 2023-12-19 | 개시 | Scotiabank | Sector Outperform |
| 2023-10-30 | 개시 | TD Cowen | Outperform |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-05-18 | 개시 | Truist | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
| 2023-03-14 | 개시 | Stifel | Buy |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-13 | 재개 | BofA Securities | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-27 | 개시 | Needham | Buy |
| 2022-07-20 | 개시 | Canaccord Genuity | Buy |
| 2022-03-01 | 개시 | BofA Securities | Buy |
| 2022-03-01 | 개시 | SVB Leerink | Outperform |
모두보기
Arcellx Inc 주식(ACLX)의 최신 뉴스
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com
Arcellx Inc stock hits all-time high at 114.27 USD By Investing.com - Investing.com Australia
Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders? – Company Announcement - Financial Times
Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com
Arcellx (NASDAQ:ACLX) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcellx Inc stock hits all-time high at 114.27 USD - Investing.com
Arcellx, Inc. (ACLX) Stock Analysis: Navigating Biotech’s Cutting Edge with Strategic Alliances - DirectorsTalk Interviews
Cowen Downgrades Arcellx, Inc. (ACLX) to Hold on March 2, 2026 - Meyka
ACLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance - Yahoo Finance
Arcellx President Sells $10M Worth of Shares After Acquisition Announcement - The Globe and Mail
TD Cowen Downgrades Arcellx to Hold From Buy - marketscreener.com
Arcellx President Sells $10 Million Worth of Shares After Acquisition Announcement - Yahoo Finance
Arcellx stock rating cut to Hold by TD Cowen on Gilead deal - Investing.com UK
Citigroup Inc. Sells 13,427 Shares of Arcellx, Inc. $ACLX - MarketBeat
TD Asset Management Inc Buys 129,248 Shares of Arcellx, Inc. $ACLX - MarketBeat
Vanguard Group Inc. Sells 37,798 Shares of Arcellx, Inc. $ACLX - MarketBeat
Insider Selling: Arcellx (NASDAQ:ACLX) Insider Sells 89,916 Shares of Stock - MarketBeat
Arcellx CEO Elghandour sells $10.2 million in ACLX stock - Investing.com
Tax-withholding sale by Arcellx (NASDAQ: ACLX) director Elghandour - Stock Titan
Arcellx, Inc. Hits Day High with 77.43% Surge in Stock Price - Markets Mojo
E-Trade Financial (NASDAQ: ACLX) files Form 144 listing 164,548 RSU shares - Stock Titan
Taxation With Representation: Linklaters, Wilson Sonsini - Law360
Gilead Sciences Inc Stock Moved Up by 3.72% on Feb 27: What Investors Need To Know - TradingKey
Arcellx, Inc. Experiences Evaluation Revision Amid Strong Market Performance and Volatility - Markets Mojo
Arcellx (ACLX) Posts US$228.9m TTM Loss Testing Bullish Profitability Narratives - Sahm
Arcellx (NASDAQ:ACLX) Announces Earnings Results, Meets Estimates - MarketBeat
Arcellx, Inc. SEC 10-K Report - TradingView
Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ACLX SEC FilingsARCELLX INC 10-K, 10-Q, 8-K Forms - Stock Titan
Guggenheim Downgrades Arcellx to Neutral From Buy, Adjusts PT to $115 From $120 - marketscreener.com
Arcellx, Inc. Opens with a 77.48% Gain, Outperforming S&P 500's 0.69% Increase - Markets Mojo
Gilead’s Arcellx Deal And HIV Data Reframe Growth And Valuation Story - Sahm
Guggenheim downgrades Arcellx stock rating on Gilead acquisition By Investing.com - Investing.com Nigeria
Guggenheim downgrades Arcellx stock rating on Gilead acquisition - Investing.com India
Arcellx, Inc. Hits New 52-Week High of $114.26, Up 110% Yearly - Markets Mojo
Insider sells 19,675 shares — E-TRADE Financial (ACLX) files Form 144 - Stock Titan
Arcellx (ACLX) CFO reports tax-driven share sale after exercising 20,530 units - Stock Titan
Arcellx CFO Michelle Gilson Sells Shares to Cover Tax Obligations - TradingView
Is It Too Late To Consider Arcellx (ACLX) After Its Recent Share Price Surge? - Yahoo Finance
Arcellx set to report earnings amid pending Gilead acquisition By Investing.com - Investing.com South Africa
Arcellx set to report earnings amid pending Gilead acquisition - Investing.com
Gilead Snaps Up Arcellx For $115 Per ShareA $7.8 Billion Bet On Cancer Therapy - Bitget
Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy - Benzinga
Arcellx (NASDAQ:ACLX) Downgraded to Hold Rating by Evercore - MarketBeat
Arcellx (NASDAQ:ACLX) Lowered to Hold Rating by Leerink Partners - MarketBeat
Arcellx Inc (ACLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):